Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ivermectin for asymptomatic Plasmodium falciparum infection in Gabonese adults
PACTR201908520097051Phase 1Completed
- Sponsor
- Centre de Recherches Médicales de Lambaréné
- Start
- May 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1 trial of ivermectin in malaria and Falciparum malaria (PF) (3 arms), sponsored by Centre de Recherches Médicales de Lambaréné. Primary endpoints: Time to 90% parasite reduction for at least 8 hours assessed by microscopy and Number and occurrence of related serious adverse events and Grade 3 adverse events. Started May 2019; status: completed.
02
Drugs
ivermectin
03
Conditions
malariaFalciparum malaria (PF)
Beyond the preview
Go deeper on PACTR201908520097051.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on PACTR201908520097051.